Fifth Third Bancorp
CHRS icon

Fifth Third Bancorp’s Coherus Oncology CHRS Stock Holding History

Fifth Third Bancorp’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-440
Closed -$1.65K – 2517
2023
Q3 		$1.65K Buy
440
+111
+34% +$513 ﹤0.01% 2408
2023
Q2 		$1.41K Buy
329
+26
+9% +$153 ﹤0.01% 2460
2023
Q1 		$2.07K Sell
303
-53
-15% -$411 ﹤0.01% 2557
2022
Q4 		$2.82K Buy
356
+110
+45% +$846 ﹤0.01% 2356
2022
Q3 		$2K Hold
246
– – ﹤0.01% 2402
2022
Q2 		$2K Buy
+246
New +$2.14K ﹤0.01% 2418
2022
Q1 		– Sell
-409
Closed -$7K – 2679
2021
Q4 		$7K Buy
409
+297
+265% +$5.19K ﹤0.01% 2215
2021
Q3 		$2K Buy
+112
New +$1.64K ﹤0.01% 2428
2020
Q2 		– Sell
-17,545
Closed -$285K – 2092
2020
Q1 		$285K Buy
17,545
+94
+0.5% +$1.74K ﹤0.01% 739
2019
Q4 		$314K Buy
17,451
+1,854
+12% +$34.2K ﹤0.01% 802
2019
Q3 		$316K Buy
+15,597
New +$312K ﹤0.01% 779

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fifth Third Bancorp's CHRS Position: Q4 2023 in Review

Fifth Third Bancorp sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 440 shares — an estimated $1.65K sold.

Fifth Third Bancorp first reported a position in CHRS in Q3 2019 and held it in 11 quarters. The position peaked at $316K in Q3 2019. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Fifth Third Bancorp reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Fifth Third Bancorp sold 440 Coherus Oncology shares in Q4 2023, an estimated $1.65K.
  • Fifth Third Bancorp first reported a position in Coherus Oncology in Q3 2019 and held it in 11 quarters.
  • Fifth Third Bancorp's Coherus Oncology position peaked at $316K in Q3 2019.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Fifth Third Bancorp's 13F filing for Q4 2023, filed 19 Jan 2024.